Target type: biologicalprocess
The selective autophagy process in which a peroxisome is degraded by macroautophagy. [GOC:autophagy, PMID:12914914, PMID:16973210]
Pexophagy is a highly specialized form of autophagy that specifically targets peroxisomes for degradation. Peroxisomes are single-membrane-bound organelles found in almost all eukaryotic cells, playing crucial roles in various metabolic processes, including fatty acid β-oxidation, reactive oxygen species (ROS) detoxification, and biosynthesis of plasmalogens. Unlike general autophagy, which sequesters bulk cytoplasm, pexophagy exhibits a selective nature, ensuring the precise degradation of peroxisomes while preserving other cellular components. This specificity is achieved through intricate signaling pathways and a dedicated set of proteins that recognize and target peroxisomes for autophagic engulfment.
The process of pexophagy begins with the formation of a double-membrane structure known as the phagophore. This membrane originates from the endoplasmic reticulum (ER) and expands to envelop the targeted peroxisome. As the phagophore encloses the peroxisome, it forms a double-membrane vesicle called the autophagosome. The autophagosome then fuses with a lysosome, a cellular organelle containing hydrolytic enzymes. Inside the lysosome, the peroxisome is broken down into its constituent components, including proteins, lipids, and nucleic acids, which are recycled back into the cell.
Pexophagy is tightly regulated and can be triggered by various stimuli, including changes in nutrient availability, oxidative stress, and developmental cues. For instance, during periods of starvation, cells may degrade peroxisomes to provide energy and building blocks for survival. Conversely, pexophagy can also be induced by an increase in ROS production within peroxisomes, which can be detrimental to the cell. This selective removal of damaged peroxisomes ensures the maintenance of cellular homeostasis and prevents the accumulation of harmful ROS.
The molecular mechanisms underlying pexophagy are complex and involve a coordinated interplay of several key proteins. One crucial player is Atg8, a ubiquitin-like protein that conjugates to the phagophore membrane and acts as a receptor for cargo recognition. In pexophagy, Atg8 interacts with specific peroxisome-associated proteins, such as Pex3 and Pex14, facilitating the selective engulfment of peroxisomes. Other proteins involved in pexophagy include the autophagy-related proteins Atg5, Atg7, and Atg12, which are essential for phagophore elongation and closure.
The importance of pexophagy is highlighted by its involvement in various physiological processes and diseases. For instance, defects in pexophagy can lead to the accumulation of peroxisomes, resulting in various disorders, including Zellweger syndrome and neonatal adrenoleukodystrophy. These disorders are characterized by severe neurological and developmental impairments, demonstrating the crucial role of pexophagy in maintaining cellular function and health.
In conclusion, pexophagy is a fundamental cellular process that ensures the selective degradation and recycling of peroxisomes. This intricate mechanism involves specific signaling pathways, specialized proteins, and a coordinated series of events, ultimately contributing to cellular homeostasis and overall organismal health. Understanding the molecular basis of pexophagy provides insights into the regulation of organelle turnover, the pathogenesis of related diseases, and the potential therapeutic targets for these disorders.'
"
Protein | Definition | Taxonomy |
---|---|---|
Serine-protein kinase ATM | A serine-protein kinase ATM that is encoded in the genome of human. [PRO:CNA] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
pd 173074 | aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist | |
caffeine | purine alkaloid; trimethylxanthine | adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic | |
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source | chromones; morpholines; organochlorine compound | autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector |
schizandrin b | schizandrin B: a phytogenic antineoplastic agent with anti-inflammatory activity; isolated from Schisandra plant | ||
thiourea | thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur. Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS. | one-carbon compound; thioureas; ureas | antioxidant; chromophore |
ku 55933 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source | ||
cgk 733 | diarylmethane | ||
nu 7026 | 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source | organic heterotricyclic compound; organooxygen compound | |
nu 7441 | 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source | dibenzothiophenes | |
ku-0060648 | dibenzothiophenes | ||
dactolisib | dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment. dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR | imidazoquinoline; nitrile; quinolines; ring assembly; ureas | antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor |
ku 60019 | |||
cp 466722 | quinazolines | ||
(3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine | indoles | ||
ve 821 | 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide: an antineoplastic agent; structure in first source | aromatic amide | |
torin 2 | torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties. | aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline | antineoplastic agent; mTOR inhibitor |
byl719 | proline derivative | ||
cc-115 | 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one: an mTOR kinase inhibitor; structure in first source | ||
vx-970 | berzosertib: an ATR kinase inhibitor | sulfonamide | |
etp-46464 | ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source |